MetaCap

Hemab Therapeutics (COAG) vs Replimune Group (REPL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Hemab Therapeutics is the larger company by market cap ($1.84 billion vs $1.81 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COAG+15.56%REPL+662.80%
+874%+402%-69%
May 1, 20261 yearNov 20, 2026
COAG+15.56%REPL+662.80%
+816%+375%-67%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COAG versus REPL key metrics
MetricCOAGREPL
Share price$39.29$19.07
Market cap$1.84B$1.81B
1-day change-1.43%-0.83%
YTD return—+96.19%
1-year return—+107.28%
5-year return—-34.24%
EPS (TTM)$-3.55$-2.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-313.94M
52-week high$55.42$23.54
52-week low$23.00$1.50
Distance from 52-week high-29.11%-18.99%
Analyst consensusstrong_buybuy
Avg. price target upside+60.35%+33.72%
Average volume495.96K2.48M
Shares outstanding46.73M94.80M
Employees59465
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Hemab Therapeutics

COAG stock →

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees

About Replimune Group

REPL stock →

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees

COAG vs REPL FAQ

Which is bigger, Hemab Therapeutics or Replimune Group?

Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.84B compared with $1.81B for Replimune Group (REPL).

Are Hemab Therapeutics and Replimune Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons